About US
Contact us
-
Sanofi’s Cablivi receives EC approval to treat rare blood disorderThe European Commission (EC) has granted marketing authorisation for Sanofi’s Cablivi (caplacizumab) indicated to treat adults with acquired thrombotic thrombocytopenic purpura (aTTP) episodes. Cabli2018/9/5
-
Former GSK researcher admits plot to steal trade secretsA former GlaxoSmithKline (GSK) researcher, Yu Xue, has pleaded guilty to a plot to steal the pharmaceutical company’s trade secrets for biopharmaceutical products in development to treat cancer and ot2018/9/5
-
Vertex and Genomics partner to use human genetics for precision medicinesUS-based Vertex Pharmaceuticals has signed a multi-year collaboration with British genome analysis company Genomics to leverage human genetics and data science for the discovery of precision medicin2018/9/4
-
Roquette appoints Rohit Markan as Managing Director for IndiaRoquette appoints Rohit Markan as Managing Director for India This appointment reaffirms Roquette’s leadership in India and supports the company’s growth ambitions in the country Mumbai (India), 3 Se2018/9/4
-
Chasing top HIV players, Merck scores FDA approval for 2 new drugsAfter marquee HIV drug approvals last year for Gilead and GlaxoSmithKline, Merck will follow into thecrowded marketwith two new meds. The drugmaker scored FDAapprovals for a new non-nucleoside rever2018/9/3
-
Kale yeah! Bayer caps Monsanto acquisition with living veggie billboards in St. LouisBayer’s newest billboards are literally sprouting up around St. Louis. Two boards went up last week with depictions of the iconic Gateway Arch planted in greenery—kale, collard greens and chard, speci2018/9/3
-
Bausch Health quickly revives FDA quest for ‘Significant 7’ hopeful DuobriiWhen Bausch Health’s plaque psoriasis combo drug Duobrii was rejected by the FDA in June, analysts read it as a major setback for the company’s reboot plan. But after a meeting with the FDA, that hu2018/8/31
-
Eyeing $1B annual sales, Emergent BioSolutions to buy Narcan maker Adapt for $735MEmergent BioSolutions is mobilizing its M&A war chest again. Hard on the heels of its $270 million deal for vaccine expert PaxVax, the frequent government contractor is buying Adapt Pharma and i2018/8/30
-
Targeting a market Big Pharma's fleeing, Tetraphase wins FDA nod for antibiotic XeravaJust as Big Pharmas are bailing out of antibiotics research left and right, a small biotech is pressing ahead with a new drug approval. Tetraphase Pharmaceuticals snagged an FDA nod forXerava, an in2018/8/29
-
Senators question whether Giuliani's influence scored Purdue Pharma leniency from fedsAs President Donald Trump and his administration work to tackle the opioid epidemic, two Democratic senators are looking into whether his personal attorney Rudy Giuliani secured leniency for opioid2018/8/28